MedKoo Biosciences/Rofecoxib/314273/250mg

Rofecoxibisanonsteroidalanti-inflammatorydrug(NSAID)thathasnowbeenwithdrawnoversafetyconcerns.Rofecoxibexhibitsanti-inflammatory,analgesic,andantipyreticactivitiesinanimalmodels.Themechanismofactionofrofecoxibisbelievedtobeduetoinhibitionofprostaglandinsynthesis,viainhibitionofcyclooxygenase-2(COX-2).Attherapeuticconcentrationsinhumans,rofecoxibdoesnotinhibitthecyclooxygenase-1(COX-1)isoenzyme.Studiestoelucidatethemechanismofactionoffofecoxibintheacutetreatmentofmigrainehavenotbeenconducted.

MedKooCat#:314273
Name:Rofecoxib
CAS#:162011-90-7
ChemicalFormula:C17H14O4S
ExactMass:314.06128
MolecularWeight:314.36
ElementalAnalysis:C,64.95;H,4.49;O,20.36;S,10.20

Synonym:MK966;MK966;MK966;MK0966;MK0966;MK0966;Rofecoxib;brandname:Vioxx;Ceoxx;Ceeoxx.

IUPAC/ChemicalName:4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one

InChiKey:RZJQGNCSTQAWON-UHFFFAOYSA-N

InChiCode:InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

SMILESCode:O=C1C(C2=CC=CC=C2)=C(C3=CC=C(S(=O)(C)=O)C=C3)CO1

TechnicalData

Appearance:

Solidpowder

Purity:

>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:

Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:

Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:

SolubleinDMSO.

ShelfLife:

>2yearsifstoredproperly

DrugFormulation:

ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:

0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:

293490

References

1:RahmeE,RoussyJP,LafranceJP,NedjarH,MorinS.Useofnonsteroidalantiinflammatorydrugs:isthereachangeinpatientriskprofileafterwithdrawalofrofecoxib?JRheumatol.2011Feb;38(2):195-202.doi:10.3899/jrheum.100332.Epub2010Nov15.Review.PubMedPMID:21078717.

2:BulleyS,DerryS,MooreRA,McQuayHJ.Singledoseoralrofecoxibforacutepostoperativepaininadults.CochraneDatabaseSystRev.2009Oct7;(4):CD004604.doi:10.1002/14651858.CD004604.pub3.Review.PubMedPMID:19821329;PubMedCentralPMCID:PMC4171390.

3:JakschW,DejacoC,SchirmerM.4yearsafterwithdrawalofrofecoxib:wheredowestandtoday?RheumatolInt.2008Oct;28(12):1187-95.doi:10.1007/s00296-008-0650-4.Epub2008Jul29.Review.PubMedPMID:18663451.

4:ChenYF,JobanputraP,BartonP,BryanS,Fry-SmithA,HarrisG,TaylorRS.Cyclooxygenase-2selectivenon-steroidalanti-inflammatorydrugs(etodolac,meloxicam,celecoxib,rofecoxib,etoricoxib,valdecoxibandlumiracoxib)forosteoarthritisandrheumatoidarthritis:asystematicreviewandeconomicevaluation.HealthTechnolAssess.2008Apr;12(11):1-278,iii.Review.PubMedPMID:18405470.

5:MasonRP,WalterMF,DayCA,JacobRF.Abiologicalrationaleforthecardiotoxiceffectsofrofecoxib:comparativeanalysiswithotherCOX-2selectiveagentsandNSAids.SubcellBiochem.2007;42:175-90.Review.PubMedPMID:17612051.

6:BurnierM.Thesafetyofrofecoxib.ExpertOpinDrugSaf.2005May;4(3):491-9.Review.PubMedPMID:15934855.

7:KrymchantowskiAV,BigalME.Rofecoxibinmigraine.ExpertRevNeurother.2005Jan;5(1):55-61.Review.PubMedPMID:15853474.

8:MarshallLL.Angioedemaassociatedwithaspirinandrofecoxib.AnnPharmacother.2005May;39(5):944-8.Epub2005Apr5.Review.PubMedPMID:15811906.

9:BardenJ,EdwardsJ,MooreRA,McQuayHJ.Singledoseoralrofecoxibforpostoperativepain.CochraneDatabaseSystRev.2005Jan25;(1):CD004604.Review.Updatein:CochraneDatabaseSystRev.2009;(4):CD004604.PubMedPMID:15674955.

10:GarnerSE,FidanDD,FrankishRR,JuddMG,TowheedTE,WellsG,TugwellP.Rofecoxibforrheumatoidarthritis.CochraneDatabaseSystRev.2005Jan25;(1):CD003685.Review.PubMedPMID:15674912.

11:GarnerSE,FidanDD,FrankishR,MaxwellL.Rofecoxibforosteoarthritis.CochraneDatabaseSystRev.2005Jan25;(1):CD005115.Review.PubMedPMID:15654705.

12:ScheenAJ.[Withdrawalofrofecoxib(Vioxx):whataboutcardiovascularsafetyofCOX-2selectivenon-steroidalanti-inflammatorydrugs?].RevMedLiege.2004Oct;59(10):565-9.Review.French.PubMedPMID:15623076.

13:LizÃ¡nTudelaL,MagazMarquÃ©sS,VarelaMorenoC,RiesgoBucherY.[Analysisofcost-minimizationtreatmentwithparacetamolorCOX-2inhibitors(rofecoxib)forpainfromarthrosisofthekneeorhip].AtenPrimaria.2004Dec;34(10):534-40.Review.Spanish.PubMedPMID:15607056.

14:SzalatA,KrasilnikovI,BlochA,MeirK,RubingerD,MevorachD.Acuterenalfailureandinterstitialnephritisinapatienttreatedwithrofecoxib:casereportandreviewoftheliterature.ArthritisRheum.2004Aug15;51(4):670-3.Review.PubMedPMID:15334443.

15:BardenJ,EdwardsJ,MooreRA,McQuayHJ.Singledoseoralrofecoxibforpostoperativepain.CochraneDatabaseSystRev.2004;(1):CD004604.Review.Updatein:CochraneDatabaseSystRev.2005;(1):CD004604.PubMedPMID:14974074.

16:SchmidtH,WoodcockBG,GeisslingerG.Benefit-riskassessmentofrofecoxibinthetreatmentofosteoarthritis.DrugSaf.2004;27(3):185-96.Review.PubMedPMID:14756580.

17:PhelanKM,MosholderAD,LuS.Lithiuminteractionwiththecyclooxygenase2inhibitorsrofecoxibandcelecoxibandothernonsteroidalanti-inflammatorydrugs.JClinPsychiatry.2003Nov;64(11):1328-34.Review.PubMedPMID:14658947.

18:CoulterDM,ClarkDW,SavageRL.Celecoxib,rofecoxib,andacutetemporaryvisualimpairment.BMJ.2003Nov22;327(7425):1214-5.Review.PubMedPMID:14630760;PubMedCentralPMCID:PMC274063.

19:WeirMR,SperlingRS,ReicinA,GertzBJ.SelectiveCOX-2inhibitionandcardiovasculareffects:areviewoftherofecoxibdevelopmentprogram.AmHeartJ.2003Oct;146(4):591-604.Review.PubMedPMID:14564311.

20:AhujaN,SinghA,SinghB.Rofecoxib:anupdateonphysicochemical,pharmaceutical,pharmacodynamicandpharmacokineticaspects.JPharmPharmacol.2003Jul;55(7):859-94.Review.PubMedPMID:12906745.

对照品标准品，生物试剂盒，gibco胎牛血清，试剂采购网，中国试剂网，细胞因子试剂盒

MedKoo Biosciences/Rofecoxib/314273/250mg

TechnicalData

References